Benzinga - by Benzinga Insights, Benzinga Staff Writer.
WARBURG PINCUS CO, Director at Sotera Health (NASDAQ:SHC), reported an insider sell on March 6, according to a new SEC filing.
What Happened: CO's decision to sell 16,594,363 shares of Sotera Health was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value of the sale is $237,423,848.
The latest update on Thursday morning shows Sotera Health shares down by 0.0%, trading at $14.23.
Get to Know Sotera Health Better Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Sotera Health: A Financial Overview Revenue Growth: Over the 3 months period, Sotera Health showcased positive performance, achieving a revenue growth rate of 23.31% as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
- Gross Margin: The company sets a benchmark with a high gross margin of 58.05%, reflecting superior cost management and profitability compared to its peers.
- Earnings per Share (EPS): With an EPS below industry norms, Sotera Health exhibits below-average bottom-line performance with a current EPS of 0.14.
Valuation Overview:
- Price to Earnings (P/E) Ratio: Sotera Health's current Price to Earnings (P/E) ratio of 79.06 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
- Price to Sales (P/S) Ratio: The Price to Sales ratio is 3.84, which is lower than the industry average. This suggests a possible undervaluation based on sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): The company's EV/EBITDA ratio 14.88 is below the industry average, indicating that it may be relatively undervalued compared to peers.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Unmasking the Significance of Insider Transactions Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
Cracking Transaction Codes Navigating through the landscape of transactions, investors often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Sotera Health's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.